Japanese
Title中枢性ベンゾジアゼピン受容体イメージング剤123I - イオマゼニルの第2相臨床試験 (第2報) - 各種脳疾患における臨床的有用性の検討 -
Subtitle技術報告
Authors鳥塚莞爾*1, 上村和夫*2, 融道男*3, 米倉義晴*4, 中川原譲二*5, 福山秀直*6, 松田一己*7, 森本清*8
Authors(kana)
Organization*1福井医科大学(現 ; 京都大学名誉教授), *2秋田県立脳血管研究センター, *3東京医科歯科大学神経精神科, *4京都大学脳病態生理学講座(現 ; 福井医科大学高エネルギー医学研究センター生態イメージング研究部門), *5中村記念病院脳神経外科, *6京都大学神経内科(現 ; 脳病態生理学講座), *7国立療養所静岡東病院(てんかんセンター)脳神経外科, *8香川医科大学精神神経科
Journal核医学
Volume33
Number2
Page191-205
Year/Month1996/2
Article報告
Publisher日本核医学会
Abstract「要旨」てんかん81例, 脳血管障害82例, 中枢神経変性疾患35例および精神神経障害14例を対象に123I-イオマゼニルSPECTの臨床的有用性を検討した. てんかんでは, 本剤の検査は発作間歇期に行われるにもかかわらず, てんかんの焦点検出の特異性は間歇期脳波のみならず発作時脳波よりも高く, 脳波で焦点部位の診断が困難な症例において有効な情報を提供するものと考えられた. また, 後期像の異常検出率は血流像より高く, てんかん発作時血流像検査と比較してもほぼ同等であった. 脳血管障害では, 後期像は血流情報とは異なり, 血行力学的脳虚血や脳虚血後の再灌流に伴う高灌流状態などの種々の病態における皮質神経細胞の脱落の程度を反映していると考えられた. 中枢神経変性疾患では, 痴呆の程度と簡易定量法により求めた結合能などの指標との間に相関が認められた. 精神神経障害では少数例での検討であったが, 異常所見出現率は形態学的検査に比べ本剤の方が高率であった.
Practice臨床医学：一般
Keywords123I-iomazenil, Benzodiazepine receptor, Central nervous system disorders, Phase 2 study, Neuronal damage.
English
TitlePhase 2 Clinical Study of 123I - Iomazenil in Various Cerebral Diseases : Part 2 - Clinical Evaluation of Central - type Benzodiazepine Receptor Imaging with 123I - Iomazenil SPECT -
SubtitleTechnical Reports
AuthorsKanji TORIZUKA*1, Kazuo UEMURA*2, Michio TOHRU*3, Yoshiharu YONEKURA*4, Jyoji NAKAGAWARA*5, Hidenao FUKUYAMA*6, Kazumi MATSUDA*7, Kiyoshi MORIMOTO*8
Authors(kana)
Organization*1Fukui Medical School(currently Professor Emeritus, Kyoto University), *2Akita Research Institute for Brain and Blood Vessels, *3Department of psychiatry, Tokyo Medical and Dental University, *4Department of Brain Pathophysiology, Kyoto University(currently Biomedical Imaging Research Center, Fukui Medical School), *5Department of Neurosurgery, Nakamura memorial Hospital, *6Department of Neurology(currently Department of Brain Pathophysiology), Kyoto University, *7Department of Neurosurgery, National Epilepsy Center, Shizuoka-Higashi Hospital, *8Department of Neuropsychiatry, Kagawa Medical School
JournalThe Japanese Journal of nuclear medicine
Volume33
Number2
Page191-205
Year/Month1996/2
ArticleReport
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary]A phase 2 clinical study of 123I-iomazenil(IMZ)was performed to evaluate its clinical usefulness as central-type benzodiazepine receptor imaging agent in 81 cases with epilepsy, 82 cases with cerebrovascular diseases(CVD), 35 cases with degenerative disorders and 14 cases with mental disorders. In epilepsy, IMZ SPECT images for detection of epileptic foci showed relatively high specificity compared with EEG recording in not only interictal but also ictal state, in spite of the fact that IMZ SPECT images was performed during interictally. It was surmised that IMZ SPECT provides valuable clinical information for detection of epileptic foci which are hard to be diagnosed by EEG. The frequency of abnormal findings by IMZ late images was higher than that by interictal blood flow images and comparable to that by ictal blood flow images. In patients with CVD, different observations were obtained between IMZ late images and blood flow images ; for example, in regions of hemodynamic cerebral ischemia, postischemic reperfusion and other pathological perfusion, IMZ late images seemed to reflect the degree of cortical neuronal loss. In patients with degenerative disorders, the binding potential(calculated by a simple quantitative method for IMZ)and other parameters correlated with the dementia score. While the number of examined cases with mental disorders was limited, the frequency of abnormal findings with IMZ imaging was higher than that with morphological imaging.
PracticeClinical medicine
Keywords123I-iomazenil, Benzodiazepine receptor, Central nervous system disorders, Phase 2 study, Neuronal damage.

【全文PDF】